Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
GlycoMimetics Q1 EPS $(0.180) Beats $(0.300) Estimate, Sales $9.000K
11:05am, Friday, 01'st May 2020GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020
11:00am, Friday, 01'st May 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 we
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs May 1.)
Arcturus Therapeutics Ltd (...
Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications
01:00pm, Thursday, 30'th Apr 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 202
GlycoMimetics (GLYC) Scheduled to Post Earnings on Friday
10:36am, Thursday, 30'th Apr 2020
GlycoMimetics (NASDAQ:GLYC) will issue its quarterly earnings data before the market opens on Friday, May 1st. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Pe
‘We’ve done what should normally take six months in about four weeks’
09:00am, Tuesday, 28'th Apr 2020
Dr Anne Jones, CEO of Genomics Medicine Ireland, discusses the company’s efforts to provide reagents to help scale up Covid-19 testing.
GlycoMimetics (NASDAQ:GLYC) Cut to Hold at Zacks Investment Research
05:36am, Tuesday, 28'th Apr 2020
GlycoMimetics (NASDAQ:GLYC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks,
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s
GlycoMimetics to Report First Quarter Financial Results on May 1, 2020
01:00pm, Friday, 24'th Apr 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET.
Zacks: Analysts Anticipate GlycoMimetics Inc (NASDAQ:GLYC) to Announce -$0.30 EPS
09:46am, Friday, 24'th Apr 2020
Equities research analysts expect that GlycoMimetics Inc (NASDAQ:GLYC) will post earnings of ($0.30) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued est
12 companies that are actively hiring in Ireland right now
07:50am, Thursday, 23'rd Apr 2020
From software engineering to business development, these companies are all hiring for new talent right now.
GlycoMimetics (NASDAQ:GLYC) Rating Increased to Buy at Zacks Investment Research
05:50am, Thursday, 23'rd Apr 2020
GlycoMimetics (NASDAQ:GLYC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports
GlycoMimetics' Focus Is On AML Therapy
08:28pm, Friday, 17'th Apr 2020
GlycoMimetics is conducting a Phase 3 trial of Uproleselan for acute myeloid leukemia. Cash on hand is sufficient to get to the top-line data release. The compa
GlycoMimetics (NASDAQ:GLYC) Stock Rating Lowered by Zacks Investment Research
07:28am, Friday, 17'th Apr 2020
GlycoMimetics (NASDAQ:GLYC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com repo
AQR Capital Management LLC Makes New $100,000 Investment in GlycoMimetics Inc (NASDAQ:GLYC)
09:42am, Tuesday, 14'th Apr 2020
AQR Capital Management LLC bought a new position in shares of GlycoMimetics Inc (NASDAQ:GLYC) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 1
